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TofacitinibThe global tuberculosis (TB) epidemic and the spread ofmulti- and extensively-drug resistant strains ofMycobac-
terium tuberculosis (M.tb) have been fueled by low adherence to following lengthy treatment protocols, and the
rapid spread of HIV (Human Immunodeﬁciency Virus). Persistence of the infection in immunocompetent indi-
viduals follows from the ability of M.tb to subvert host immune responses in favor of survival within macro-
phages. Alternative host-directed strategies are therefore being currently sought to improve treatment efﬁcacy
and duration. In this study, we evaluated tofacitinib, a new oral Janus kinase (JAK) blocker with anti-
inﬂammatory properties, in shortening tuberculosis treatment. BALB/c mice, which are immunocompetent,
showed acceleration ofM.tb clearance achieving apparent sterilization after 16 weeks of adjunctive tofacitinib
therapy at average exposures higher than recommended in humans, while mice receiving standard treatment
alone did not achieve clearance until 24 weeks. True sterilization with tofacitinib was not achieved until ﬁve
months. C3HeB/FeJ mice, which show reduced pro-inﬂammatory cytokines duringM.tb infection, did not show
improved clearance with adjunctive tofacitinib therapy, indicating that the nature of granulomatous lesions
and host immunity may inﬂuence responsiveness to tofacitinib. Our ﬁndings suggest that the JAK pathway
could be explored further for host-directed therapy in immunocompetent individuals.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) claims 1.6 million lives every year. Efforts to control
the global epidemic are further undermined by an ever-increasing subset
of Mycobacterium tuberculosis (M.tb) strains that is resistant to existing
anti-TB drugs. In affected immune-competent individuals with no active
disease, the bacilli remain protected at the primary sites of infection in
granulomas that provide immunologic and physical barrier to ensure bac-
terial survival, and may promote the development of persistent bacteria
or persisters, reduced drug penetration, and diminished antimicrobial
killing until loss of immune protection reactivates disease. A leading hy-
pothesis is that persisters develop as an adaptation to host immune pres-
sure within granulomatous lesions. Under this hypothesis, persisters
represent phenotypic variants which, due to immunologic stress, enter a
slow-sporadic, or non-growing state which makes them tolerant to anti-
microbial killing (McCune et al., 1957). This hypothesis suggests that a
strategy to accelerate cure is to prevent entry into the poorly growingearch, Johns Hopkins University
, MD 21231, USA.
Infectious Diseases, DIR/LPD,
. This is an open access article underpersister phenotypic state and to reactivate quiescent lesions by transient
immune modulation. This transient reactivation and subsequent antimi-
crobial killing, or “wake ‘em and whack ’em” strategy, has been recently
advocated as one of the novel approaches to combat the spread of tuber-
culosis by the global Stop TB Partnership (Robertson et al., 2012), which, in
collaborationwith theWorld Health Organization, recently set the goal of
eliminating tuberculosis world-wide by 2050.
The mechanisms by whichM.tb persisters modulate host responses
to ensure survival remain unclear. It is believed that a balance between
pro-inﬂammatory cytokines such as IL-12, IFN-γ, and TNF-α, and anti-
inﬂammatory cytokines such as IL-10 plays a role (Cilfone et al., 2013;
Marino et al., 2015). An effective reactivation strategy would therefore
aim at tipping this balance by either suppressing pro-inﬂammatory re-
sponses, or promoting anti-inﬂammatory responses, or both. In fact,
an increased incidence of tuberculosis has been noted among patients
on TNF-α inhibitors (Salgado and Gomez-Reino, 2011), and several lab-
oratory and human clinical studies have demonstrated the efﬁcacy of
adding TNF-α inhibitors (TNF-Is) to antibacterial chemotherapy for TB
(Wallis et al., 2004; Skerry et al., 2012); TNF neutralization also induces
reactivation in nonhuman primates with latent tuberculosis infection
(Lin et al., 2010). However in this model, TNF neutralization also alters
chemokine receptor expression, and impaired cellular recruitment,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tantly, at least in a third of animals, reactivation was not achieved fol-
lowing anti-TNF treatment, indicating that TNF may not be a critical
factor in maintaining persisters (Lin et al., 2010).
In efforts to block pro-inﬂammatory responses, we recently showed
that tofacitinib, a Janus kinase (JAK) inhibitor that was FDA-approved in
2012 for treating rheumatoid arthritis and ulcerative colitis (Traynor,
2012; Sandborn et al., 2012), blocked immune containment and
promoted bacterial replication during chronic TB in the mouse
paucibacillary model in the absence of anti-TB drugs (Maiga et al.,
2012). Tofacitinib targets JAK3 (IC50 2 nM) and to a lesser degree JAK2
(IC50 20nM) (Pesu et al., 2008). Inhibition of JAK3 reduces responsiveness
tomultiple pro-inﬂammatory cytokines including IL-2, IL-4, IL-15, and IL-
21. In doing so tofacitinib inhibits the maturation of CD4+CD25+ (IL-2
receptor-bearing) Teff cells, though it appears to spare CD4+CD25+ Treg
function (Sewgobind et al., 2010). Inhibition of JAK2 blocks responsive-
ness to IL-6 and IFN-γ. In this study, in order to adopt the “wake-‘em to
whack ’em” strategy for reducing TB treatment times, we evaluated
tofacitinib as an adjuvant, host-directed therapy for TB while simulta-
neously treating with the standard anti-TB antibiotics for six months.
2. Materials and Methods
2.1. Animals, Drugs, and Bacteria
Sixweek-old female BALB/c (Charles River, MD, USA) and C3HeB/FeJ
(Jackson Laboratories, ME, USA) mice were used with three mice per
time point (PK studies), ﬁve mice per time point (chemotherapy stud-
ies), and 10 mice per regimen (relapse studies). Procedures were ap-
proved by the Johns Hopkins University Animal Care and Use
Committee. Tofacitinib was purchased from LC Laboratories (Woburn,
MA, USA) and administered by oral gavage in 0.5% (w/v) carboxymeth-
ylcellulose (Sigma-Aldrich, MO, USA) and 0.025% (vol/vol) Tween-20
(Sigma-Aldrich, MO, USA). All other drugs were obtained and used in
doses as previously described (Gupta et al., 2013). They were adminis-
tered by oral gavage in a total volume of 0.2 mL water. M.tb strain
H37Rv was cultured at 37 °C in Middlebrook 7H9 broth (Becton-
Dickinson, NJ, USA) supplemented with 10% (vol/vol) oleic acid-
albumin–dextrose-catalase (OADC Becton-Dickinson, NJ, USA), 5%
(vol/vol) glycerol and 0.05% (vol/vol) Tween-80 (Sigma-Aldrich, MO,
USA). Susceptibility testing to isoniazid and rifampin (both obtained
from Sigma-Aldrich, MO, USA) was performed using the microplate
alamar blue assay (MABA) (Cho et al., 2015).
2.2. Pharmacokinetic Study
Rifampin was administered to mice at 10 mg/kg/day for seven days
to achieve CYP3A and P-glycoprotein induction (Matheny et al., 2004).
Tofacitinib was then administered in two doses 6 h apart for a total
dose of 15, 22.5 or 30 mg/kg; the second dose was co-administered
with rifampin at 10 mg/kg. Blood was collected from mice at 1, 2, 3, 4,
6, 7, 8, 10, 12 and 24h post-administration of the ﬁrst dose of tofacitinib.
Serum samples were separated by centrifugation and stored at−80 °C
until analysis. Drug levelsweremeasured using anAB-Sciex QTrap 5500
LC/MS/MS (MA, USA) using 0.1% formic acid in deionizedwater (mobile
phase A) and 0.1% formic acid in acetonitrile (mobile phase B) at a ﬂow
rate of 200 μl/min with an XTerra®MS column (C18, 2.1 mm × 50 mm,
particle size 3.5 μm,Waters Corporation,MA, USA). Quantitation of drug
levels was performed usingm/z transitions of 823.1/791.2 for rifampin
and 313.4/149.1 for tofacitinib, and the chromatograms were analyzed
using the Multiquant 2.1 software from AB-Sciex (MA, USA).
2.3. TB Chemotherapy Models
A mouse model of chronic TB was used for this study (Rosenthal
et al., 2012). Mice were infected with M.tb H37Rv by aerosol (usingthe Glas-Col inhalation exposure system, IN, USA) to implant 2 log10
CFUs on day 1, and ﬁve mice were sacriﬁced the day after infection
(time point: week −8 of drug treatment) to determine bacterial
implantation. Treatment was initiated 8 weeks post-infection (time
point: day 0), when the lung bacterial load stabilized at around 6 log10
CFUs for BALB/c mice and 5 weeks post-infection when the lung bacte-
rial burden was around 8.5 log10 CFUs for C3HeB/FeJ mice (see Table S1
for BALB/c mouse experimental scheme). Treatment regimens were
administered 5 days per week. Control regimens were no drug treat-
ment and the standard short-course regimen: two months (the inten-
sive phase) of daily isoniazid (H), rifampin (R) and pyrazinamide
(Z) followed by 4 months (the continuation phase) of daily isoniazid
and rifampin. The two test regimens for BALB/c study included the
following changes to the standard treatment: the addition of tofacitinib
and the replacement of pyrazinamide with tofacitinib. In the C3HeB/FeJ
mouse study, only the addition of tofacitinib to the standard treatment
was used. Five mice from each treatment group were sacriﬁced every
4 weeks post-treatment's initiation for lung CFU assessment. To assess
the impact of discontinued treatment on relapse, drug administration
was stopped for 10 mice in each group after 4 and 5 months of treat-
ment for BALB/C study, and after 3 and 4 months of drug treatment
for C3HeB/FeJ study. These mice, as well as 10 mice from each group
that completed the full 6 months of treatment, were kept for an
additional 3 months after ending treatment, at which point the mice
were sacriﬁced for lung CFU assessment. Study endpoints included
lung CFU counts, time to culture-negative status, and proportion of
relapse (culture-positive lungs 3 months after ending treatment).
2.4. Cytokine Responses
Bonemarrow-derivedmacrophages (BMDM) cells from BALB/c and
C3HeB/FeJ mice were isolated following published protocol (Skinner
et al., 1994) and infectedwith H37Rv for 2 h at amultiplicity of infection
(MOI) of 1:10. Cells were washed and resuspended in MEMmedia (Life
Technologies, CA, USA) overnight with or without treatment with
tofacitinib at 300 nM. TNF-α and interleukin-1 beta (IL-1β) were
measured 24, 48 and 96 h later by ELISA (R&D Systems, MN, USA).
The data shown represent three biological and three technical
replicates.
2.5. Statistical Analysis
Lung CFU counts (x) were log-transformed as log10 (x + 1) prior to
analysis. The Mann–Whitney U test was used to determine statistical
signiﬁcance between groups. To determine the differences in cytokine
responses between BMDMs of the two different mouse strains, data
were analyzed by two-way ANOVA with the Bonferroni's test applied
to correct formultiple comparisons. Data analyses, including pharmaco-
kinetic analyses, were performed with Prism 6.0 (GraphPad Software,
CA, USA), and measures of variations expressed as ±SD.
3. Results
3.1. Pharmacokinetics of Tofacitinib and Rifampin Co-Administration
Because of the known tofacitinib-rifampin drug-drug interaction
due to rifampin-mediated CYP3A4 induction, we ﬁrst conducted a PK
study to establish effective rifampin and tofacitinib doses in mice for
drug co-administration. The concentration of tofacitinib required to
inhibit JAK tyrosine kinase activity is 100 nM (31.2 ng/mL), and treat-
ment with recommended doses achieves an AUC0–24 of ~3250 nM·H
(1014 ng/mL·H) with an elimination half-life of ~3 h (Dowty et al.,
2014). First we assessed the effect of chronic rifampin exposure on
tofacitinib levels. Rifampin was administered daily for seven days
prior to a one-day co-administration of tofacitinib and rifampin. Since
rifampin is only dosed once daily and tofacitinib twice, the ﬁrst dose
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dose in conjunctionwith rifampin. After steady state rifampin exposure,
the peak serum concentration achieved by all three doses of tofacitinib
testedwas 500–800 ng/mL,well above the concentration required to in-
hibit JAK tyrosine kinase activity (100 nMor 31.2 ng/mL).With rifampin
pre-treatment and co-administration, the 24-hour area under the curve
(AUC0–24) values for tofacitinib were 2380 ng/ml·H, 5074 ng/ml·H, and
5156 ng/ml·H for 15, 22.5 and 30mg/kg/day of tofacitinib, respectively
(Fig. 1A). All of these tofacitinib AUC0–24 values compared favorably
with typical human AUC0–24 achieved by the drug (1014 ng/mL·H).
Interestingly, we observed increased tofacitinib levels in mouse serum
on the second of the two daily doses, namely the dose that was co-
administered with rifampin at t = 6 h. This may be due to relative
saturation of the liver clearance enzymes by rifampin on this second
dose.
Next we assessed the impact of tofacitinib on rifampin levels. Co-
administration of tofacitinib with rifampin had only a modest impact
on rifampin AUC0–18 values which were 77.2, 93.1 and 102.9 g/ml·H
for mice that received 15, 22.5 and 30 mg/kg/day of tofacitinib, respec-
tively, and it had no effect on the serum concentration of rifampin
(Fig. 1B). These data suggest that tofacitinib could be administered
with the standard TB chemotherapy regimen without drug–drug inter-
actions adversely affecting drug levels. Based on these data, we selected
a tofacitinib dose of 30 mg/kg/day given in two divided doses as it gave
an elimination half-life closest that that in humans, achieved serumA
B
Fig. 1. A: Mouse serum concentrations of tofacitinib. Mouse serum concentrations of
tofacitinib after dosing at 15, 22.5 and 30 mg/kg administered at t = 0 h and t = 6 h.
A single dose of 10 mg/kg of rifampin was also administered at t = 6 h. The resulting
tofacitinib area under curve concentrations (0–24 h) were 2380, 5074, and
5156 ng/ml·H, for the three respective doses. All mice were pre-treated daily for seven
days with 10 mg/kg/day of rifampin to induce CYP3A4. B: Mouse serum concentrations
of rifampin. Mouse serum concentrations of rifampin after dosing at 10 mg/kg at t = 0 h
with tofacitinib 15, 22.5 and 30 mg/kg given at t = −6 h and t = 0 h. The resulting
rifampin area under curve concentrations (0–18 h) were 77, 93, and 103 μg/ml·H for
the respective co-administered tofacitinib dose. All mice were pre-treated daily for
seven days with 10 mg/kg/day of rifampin to induce CYP3A4.levels capable of inhibiting JAK tyrosine kinase activity for a reasonable
portion of the 24-hour treatment cycle, and did not adversely affect
rifampin levels (Cohen et al., 2010). The dose selected for our study
apparently leads to an average exposure in mice at least three to ﬁve
times higher than exposure for patients with rheumatoid arthritis
on 10 mg per day dose. However, the concentration of tofacitinib 2 h
after the dose is approximately 250–500 ng/mL with or without co-
administration of rifampin, at all doses of tofacitinib tested, suggesting
rapid hepatic and renal clearance, similar to seen in pharmacokinetic
studies in humans (Dowty et al., 2014).
3.2. Addition of Tofacitinib to Six-Month Standard TB Chemotherapy
In this study, we utilized the 6-month chronic mouse model of TB,
and standard chemotherapy (Std-Rx) consisting of 2 months of isonia-
zid (H), rifampin (R) and pyrazinamide (Z) treatment, followed by 4
months of isoniazid and rifampin (2HRZ/4HR) to address whether
inclusion of tofacitinib as an adjunctive to standard chemotherapy
(2HRZT/4HRT) may shorten TB treatment duration in both immuno-
competent BALB/c mice, and in C3HeB/FeJ mice that are deﬁcient at
the sst1 (“supersusceptibility to tuberculosis”) locus. Based on recent
reports that pyrazinamide may inhibit host inﬂammatory responses
(Manca et al., 2013), we also tested substitution of pyrazinamide with
tofacitinib in Std-Rx (2HRT/4HR) (Supplementary Table 1).
3.2.1. BALB/c Mice
We infected BALB/c mice by the aerosol route with a day-1
lung implantation of 2.40 (standard deviation [SD] 0.08) log10 CFUs.
Drug treatments commenced 8 weeks after infection, when the
bacterial lung burden was at 6.43 (SD 0.31) log10 CFUs. No signiﬁcant
differences in the different treatment groups were seen during the
ﬁrst eight weeks. However, at week 16 of treatment, mice treated
with 2HRZT/4HRT showed signiﬁcantly lower CFU counts compared to
Std-Rx of 2HRZ/4HR, with p values of 0.013 (Fig. 2A and Supplementary
Table 2). Mice receiving 2HRZT/4HRT had no detectable bacteria in the
lungs after 16 weeks of treatment, whereas the 2HRT/4HR and Std-Rx
groups required 24 weeks, to reach the same endpoint. Replacement
of pyrazinamide with tofacitinib (2HRT/4HR versus 2HRZ/4HR)
improved bacterial killing between 12 to 16 weeks of treatment
(Fig. 2A). Although pyrazinamide is known to be effective against poorly
replicating or semi-dormant bacilli, this suggests that reactivation
mediated by tofacitinib may be most active when administered
together with pyrazinamide during the bactericidal phase of treatment
(Fig. 2A between the t = 0 and 4 weeks).
Our earlier histopathology studies showed that lungs from BCG
immunized, tofacitinib-treated mice challenged with H37Rv showed
moderate lesions of leukocyte aggregation at 4 weeks of tofacitinib
treatment compared to BCG immunized, untreated mice challenged
with H37Rv, conﬁrming bacterial reactivation mediated by tofacitinib
(Maiga et al., 2012). It was interesting to note that the relapse rate
did not differ among mouse groups receiving Std-Rx alone or those
receiving it in addition to tofacitinib. In contrast, replacement of
pyrazinamide by tofacitinib (2HRT/4HR group) was detrimental
when treatment was stopped at month 4 with a higher relapse rate in
the 2HRT/4HR group (80%) compared to the Std-Rx group (20%)
(Table 1).
3.2.2. C3HeB/FeJ Mice
C3HeB/FeJ inbredmice are extremely susceptible toM.tb due to nat-
urally occurring mutations in the intracellular pathogen resistance 1
(Ipr1) isoform of the interferon-inducible 75 (Iﬁ75) gene (Pan et al.,
2005). Infected mice develop marked lung pathology, with necrotic
granulomas more closely resembling human lesions that harbor latent
bacilli (“Kramnik mouse model”). We therefore tested the efﬁcacy of
tofacitinib as an adjunct to chemotherapeutic drugs in infected
C3HeB/FeJ mice. We infected the mice by the aerosol route with a day
AB
Fig. 2.A:Growth ofM.tb in BALB/cmouse lungs during treatment. BALB/cmousemean lung log10 CFU counts for thedosing regimens shown in the inset.Mice infected by the aerosol route
achieved a day-1 lung implantation of 2.40 (standard deviation [SD] 0.08) log10 CFUs, and 8 weeks after infection at the initiation of treatment the bacterial lung burden was at 6.43 (SD
0.31) log10 CFUs. No differences across the groupswere seenduring theﬁrst 8weeks. However,mice treatedwith 2HRZT/4HRT had lower lung bacterial burden thanmice treatedwith the
Std-Rx of 2HRZ/4HR at week 16 (P= 0.013). The group receiving 2HRT/4HR showed lower but not statistically signiﬁcant CFU counts at 16 weeks (P= 0.0937). B: Cytokine levels from
BALB/c and C3HeB/FeJ bonemarrow-derivedmacrophages (BMDMs) following infection withM.tb and tofacitinib treatment. Differences in cytokine levels of infected BALB/c and C3HeB/
FeJ bonemarrow-derived macrophages (BMDMs) upon infection withM.tb. The BMDMs of BALB/c and C3HeB/FeJ BMDMs were infected with H37Rv for 2 h at a multiplicity of infection
(MOI) of 1:10. TNF-α and IL-1β levels were measured by ELISA 24, 48 and 96 h later. Data shown here, which represents three biological and technical replicates, were analyzed by two-
way ANOVA with the Bonferroni's test applied to correct for multiple comparisons. Despite similar baseline values (i.e. undetectable TNFα levels and approximately 250 pg/ml IL-1β
levels), infected BALB/c mice showed consistent and signiﬁcantly higher levels of both cytokine secretions when compared to C3HeB/FeJ mice. Addition of tofacitinib (300 nM) to
uninfected or infected cells did not alter the cytokine levels (not shown). An asterisk (*) indicates p b 0.005.
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infection the bacterial lung burden reached 8.78 (SD 0.63) log10 CFUs
with mice becoming lethargic at that point. In these mice, during the
ﬁve months of treatment with 2HRZ/3HR versus 2HRZT/3HRT, no
difference in lung CFU burdens was observed between the two
groups (Supplementary Table 3), unlike observations in BALB/c mice.Table 1
Proportions of BALB/c mice with relapse 3 months post-treatment.
Duration of treatment Proportion of mice with detectable bacilli in the
lungs
2HRZ/4HR 2HRZT/4HRT 2HRT/4HR
4 months (M4 + 3) 2/10 3/10 8/10
5 months (M5 + 3) 0/10 0/10 2/10
6 months (M6 + 3) 0/10 0/10 0/10
H: isoniazid at 25 mg/kg/day; R: rifampin at 10 mg/kg/day; Z: pyrazinamide at 150
mg/kg/day; T: tofacitinib at 30mg/kg/day; and+3: plus threemonthswithout treatment.
The columns slow the three treatment groups of BALB/cmice evaluated in this study. After
receiving treatment for 4, 5, or 6 months, groups of ten mice were removed from treat-
ment and held for 3 additional months. Following 3 months of no treatment, these mice
were sacriﬁced and the lung homogenates subjected to CFU counting. The numbers of
mice with relapse (with any detectable lung CFU) are shown.In addition, no difference was seen in 3-month relapse rates post-
treatment.
3.3. Determination of Isolates' Resistance Patterns During Treatment in the
BALB/c Chronic Model
Colonieswere isolated from different groups of BALB/cmice in order
to assess their resistance proﬁles after four months of treatment. All
isolates remained fully susceptible to isoniazid and rifampin with
minimum inhibitory concentrations of 0.04 μg/ml and 0.25 μg/ml,
respectively, indicating that no genotypic resistance developed
during mice treatment. We also determined the minimal inhibitory
concentration of tofacitinib against wild type H37Rv to be N64 μg/ml,
a level signiﬁcantly above the peak tofacitinib serum concentration in
mice during our PK experiments (3 μg/ml). In this regard, it is to be
noted that single drug treatment leads to signiﬁcantly increased num-
bers of drug-resistant colonies in infected C3HeB/FeJ mice compared
to BALB/c mice (Driver et al., 2012).
3.4. Cytokine Responses to Tofacitinib From Infected BMDM of BALB/c and
C3HeB/FeJ Mice
In order to better understand the lack of activity of tofacitinib
adjunctive therapy in C3HeB/FeJ mice, we isolated BMDMs from both
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evaluated their pro-inﬂammatory cytokine responses. Cells from both
mouse strains showed similar levels of cytokine secretion in the absence
of infection (undetectable levels of TNFα and approximately 250 pg/mL
of IL-1β). However, following M.tb infection BMDM from C3HeB/FeJ
mice, cells expressed signiﬁcantly weaker cytokine responses than
BALB/c mice (Fig. 2B). C3HeB/FeJ macrophages secreted 580 (±87)
pg/ml of TNF-α versus 705 (±37) pg/ml from BALB/c cells. For IL-1β,
C3HeB/FeJ macrophages secreted 583 (±64) pg/ml versus 811 (±67)
pg/ml from BALB/c, ﬁndings which are consistent with earlier reports
in a mouse LPS-challenge model (Ghoreschi et al., 2011). Addition of
tofacitinib to uninfected or infected cells did not alter the cytokines
expressed by BMDMs from either source. These data reveal that follow-
ing M.tb infection C3HeB/FeJ mice mount a reduced pro-inﬂammatory
response, which appears to be functional consequence of inactivation
of the intracellular pathogen resistance 1 (ipr1) gene in these mice.
Because tofacitinib acts by reducing target cell responses following
pro-inﬂammatory cytokine binding, the lack of efﬁcacy of tofacitinib
in C3HeB/FeJ mice may stem from the fact that these mice have lower
pro-inﬂammatory cytokine levels to start with and therefore also a
reduced JAK signal to be inhibited by tofacitinib. Ipr1 gene regulates
apoptotic cell death in M.tb-infected macrophages (Pan et al., 2005).
Hence it is also likely that differential cell death via apoptosis accounts
for differences in cytokine expression of BMDM from the two sources.
4. Discussion
In this study, we used a well-established mouse model of chronic
M.tb infection to evaluate the addition of tofacitinib to 6-month Std-
Rx for TB. Our data suggest that addition of tofacitinib, which is an orally
administered, FDA-approved JAK inhibitor, may be beneﬁcial in TB
treatment by reducing the time to apparent sterilization achievable
with Std-Rx. BALB/c mice receiving 2HRZT/4HRT showed complete
lung clearance ofM.tb at 16 weeks of treatment while Std-Rx alone re-
quired 24 weeks to achieve apparent sterilization. A major strength of
this study is that we tested the addition of a host-directed therapeutic
agent head-to-head against a validated, full-course, standard regimen
for TB and found a beneﬁcial effect. While other host-directed therapies
have shown enhanced clearance together with single antibiotics or
other forms of partially effective therapy, improving upon full Std-Rx
by addition of immunomodulatory drugs is more difﬁcult to achieve,
but is ultimately a goal that will be required for advancing host-
directed therapies into human clinical research. It is to be pointed out
here that the dose selected for our study leads to an average exposure
in mice at least three to ﬁve times higher than exposure for patients
with rheumatoid arthritis on a recommended dose of 10 mg per day.
Even though efﬁcacy of tofacitinib is dose-related in human rheumatoid
arthritis (Lee et al., 2014), higher doses have not been recommended
due to increased risk of serious infections and malignancies. During
the study period, we did not observe any adverse effects in mice at the
higher dose, suggesting that pharmacokinetics and drug–drug interac-
tions in mice are rather poor predictors of events in humans.
Interestingly, although tofacitinib signiﬁcantly accelerated the time
to apparent lung sterilization when added to Std-Rx in BALB/c mice, it
did not alter the time to achieve relapse-free cure, which required ﬁve
months in both the Std-Rx and 2HRZT/4HRT treatment groups
(Table 1). This suggests that despite achieving apparent clearance in
mouse lungs at 16 weeks, the 2HRZT/4HRT regimen was unable to
achieve true sterilization until the ﬁve-month time point. This ﬁnding
suggests that the acceleration of therapywith tofacitinib may not trans-
late into a more rapid non-relapsing cure. It is also reminiscent of the
well-studied apparent sterile state achieved in the Cornell mouse laten-
cymodel in mice treated with isoniazid and pyrazinamide for 12weeks
(McCune and Tompsett, 1956), and hence may not reﬂect the ability of
humans to achieve sterilization because humans are more resistant to
M.tb than mice and can mount bactericidal immunity.By inhibiting JAK3- and to a lesser degree JAK2-mediated phosphor-
ylation of activated cytokine receptors and the subsequent recruitment
of STAT transcription factors, tofacitinib reduces responsiveness to cir-
culating pro-inﬂammatory cytokines (primarily IL-2, IL-4, IL-15, and
IL21 for JAK3; and IFN-γ, IL-6, IL-12 and IL-23 for JAK2) (Pesu et al.,
2008). By blocking cytokine-mediated T cell activation, tofacitinib also
inhibits Teff cell differentiation but has limited action on Treg function
(Sewgobind et al., 2010). Tofacitinib also blocks secretion of TNF-α
and IL-1β in mice following LPS challenge (Ghoreschi et al., 2011), and
by human dendritic cells stimulated by LPS (Kubo et al., 2014), a ﬁnding
which we observed in M.tb infected BMDM (Fig. 2B). Our ﬁndings
suggest that immunomodulatory drugs such as tofacitinib could block
immune containment of M.tb and promote bacterial replication that
can be targeted by standard drugs. It is likely that other similar immuno-
modulatory drugs may perform even better.
While the anti-inﬂammatory effect of tofacitinib led to an
acceleration of M.tb clearance in wild-type BALB/c mice receiving
2HRZT/4HRT, when the same regimen was used on C3HeB/FeJ mice,
which harbor mutations in the Ipr1 gene, it had no effect, suggesting
that the effect of tofacitinib is dependent on the host biology and im-
mune response. BALB/c mice are preferred as the traditional validated
animal model for TB drug evaluation. Many studies in BALB/c mice
have been directly translated to human trials with good correlation.
On the other hand, C3HeB/FeJ mice are much more susceptible toM.tb
infection, and serve as experimental models for lesions of lung necrosis
(Driver et al., 2012). The absence of tofacitinib activity in C3HeB/FeJ
mice is also consistent with earlier observations that mice with muta-
tions in the sst1 locus mount signiﬁcantly reduced IL-6 and IL-1β
responses as well as CD4+CD25+ Teff cell responses duringM.tb infec-
tion (Pichugin et al., 2009; Yan et al., 2007). Since sst1-deﬁcient mice
display blunted pro-inﬂammatory cytokine induction and reduced IL-
2-receptor (CD25)-mediated Teff maturation, it is not surprising that
tofacitinib, which blocks receptor function for these key cytokines,
showed little effect in these mice. While tofacitinib (a broad cytokine
activation inhibitor) had no activity in C3HeB/FeJ mice, Skerry et al.
recently observed signiﬁcant acceleration of M.tb clearance with the
addition of etanercept (a speciﬁc TNF-α receptor antagonist) to Std-
Rx (Skerry et al., 2012). Hence, it is possible that the nature of the
granulomatous lesions in C3HeB/FeJ mice, which are necrotic and
hypoxic compared with those of BALB/c mice, prevents action of
tofacitinib but allows action of other anti-inﬂammatory agents such as
etanercept. Tofacitinib blocks IL-10-mediated feedback inhibition on
pro-inﬂammatory cytokine transcription in macrophages (Pattison
et al., 2012). In silico studies show that a balance of TNF-α and IL-10 con-
centrations is essential toM.tb infection control within a single granulo-
ma (Cilfone et al., 2013). In fact, in the C3HeB/FeJ mouse model of TB,
mice treated with anti-inﬂammatory drugs such as ibuprofen showed
decreased lung lesions and bacillary load, and improved survival
(Vilaplana et al., 2013). Massive neutrophilic inﬁltration is also likely
a key determinant of the development of the necrotic lesions in
C3HeB/FeJ mice and of susceptibility to TB (Marzo et al., 2014). The
above factors could determine different lung pathology and outcomes
in C3HeB/FeJ mice compared to the BALB/c mice. It is to be noted that
infected C3HeB/FeJ mice are also resistant to monotherapy including
isoniazid, pyrazinamide, and clofazimine (Driver et al., 2012; Irwin
et al., 2014), and that administration of clofazimine prior to the forma-
tion of hypoxic, necrotic granulomas leads to therapeutic efﬁcacy
(Irwin et al., 2014). Irwin et al. (Irwin et al., 2014) show that the
differential activity of clofazimine in BALB/c and C3HeB/FeJ mice is
speciﬁcally related to the granulomatous pathology in the lungs of
these mice, and not due to differences in immune function between
mouse strains, since clofazimine is also effective in immunocompro-
mised, interferon-γ knockout mice. To study the role of hypoxic
granulomas in the attenuated effect of tofacitinib in C3HeB/FeJ mice,
our future studies will therefore evaluate the efﬁcacy of 2HRZT/4HRT
regimen at earlier time points post-infection (~3 weeks), when lesions
873M. Maiga et al. / EBioMedicine 2 (2015) 868–873containing caseous necrotic material are absent. Our future studies will
also evaluate the efﬁcacy of adjunctive tofacitinib therapy at exposures
similar to doses recommended in humans.
5. Conclusion
Our ﬁndings suggest that targeting the JAK pathway may accelerate
TB treatment times when used as an adjunctive host-directed therapy
together with standard anti-tuberculous chemotherapy, even though
this may not lead to more rapid non-relapsing cure. Our data also
suggest that the nature of granulomatous lesions and host immunity
may inﬂuence responsiveness to tofacitinib.
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